Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial

被引:0
|
作者
Chen Chen [1 ]
Liang Huizhu [2 ]
He Meibo [3 ]
Duan Ruqiao [1 ]
Guan Yu [4 ]
Wang Fangfang [5 ]
Duan Liping [1 ]
机构
[1] Department of Gastroenterology, Peking University Third Hospital, Beijing, China
[2] Department of Cardiology, Peking University People’s Hospital, Beijing, China
[3] Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
[4] Department of Cardiology, Beijing Haidian Hospital, Beijing, China
[5] Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing,
关键词
Proton pump inhibitors; Histamine-2 receptor antagonists; Acute coronary syndrome; Gut microbiota;
D O I
暂无
中图分类号
学科分类号
摘要
Background: Several randomized controlled studies have suggested that the prophylactic use of proton pump inhibitors (PPIs) in intensive care unit (ICU) patients could not reduce the incidence of gastrointestinal bleeding (GIB) and may increase adverse events such as intestinal infection and pneumonia. Gut microbiota may play a critical role in the process. PPIs have been widely prescribed for GIB prophylaxis in patients with acute coronary syndrome (ACS). This study aimed to determine the short-term effects of PPI and histamine-2 receptor antagonist (H2RA) treatment on gut microbiota of ACS patients.Methods: The study was designed as a single-blind, multicenter, three-parallel-arm, randomized controlled trial conducted at three centers in Beijing, China. We enrolled ACS patients at low-to-medium risk of GIB and randomized (2:2:1) them to either PPI (n = 40), H2RA (n = 31), or control group (n = 21). The primary outcomes were the alterations in gut microbiota after 7 days of acid suppressant therapy. Stool samples were collected at baseline and 7 days and analyzed by 16S ribosomal RNA (rRNA) gene sequencing.Results: There were no significant changes in the diversity of gut microbiota after the short-term use of acid suppressants, but the abundance ofFusobacterium significantly increased and that ofBifidobacterium significantly decreased, especially in PPI users. In addition, the abundance of some pathogenic bacteria, includingEnterococcus andDesulfovibrio, was significantly elevated in the PPI users. The fecal microbiota of the PPI users included more arachidonic acid metabolism than that of control group.Conclusions: PPIs may increase the risk of infection by adversely altering gut microbiota and elevating arachidonic acid metabolism, which may produce multiple proinflammatory mediators. For ACS patients at low-to-medium risk of GIB, sufficient caution should be paid when acid-suppressant drugs are prescribed, especially PPIs.Registration: www.chictr.org.cn (ChiCTR2000029552).
引用
收藏
相关论文
共 50 条
  • [1] MULTICENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT OF SHORT-TERM PROTON PUMP INHIBITORS VERUS HISTAMINE-2 RECEPTOR ANTAGONISTS ON GUT MICROBIOTA IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Chen, Chen
    He, Meibo
    Duan, Ruqiao
    Wang, Fangfang
    Liang, Huizhu
    Guan, Yu
    Duan, Li-Ping
    GASTROENTEROLOGY, 2022, 162 (07) : S1010 - S1011
  • [2] Concerning Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists
    Xie, Jian
    Li, Lang
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (10):
  • [3] Concerning Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists Reply
    Pereg, David
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (10):
  • [4] Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke
    Momosaki, Ryo
    Yasunaga, Hideo
    Matsui, Hiroki
    Fushimi, Kiyohide
    Abo, Masahiro
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (05): : 1035 - 1040
  • [5] Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis
    Vangala, Chandan
    Niu, Jingbo
    Lenihan, Colin R.
    Mitch, William E.
    Navaneethan, Sankar D.
    Winkelmayer, Wolfgang C.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (10): : 1534 - 1541
  • [6] Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia
    Nagahara, Akihito
    Asaoka, Daisuke
    Hojo, Mariko
    Oguro, Masako
    Shimada, Yuji
    Ishikawa, Dai
    Osada, Taro
    Kawabe, Masato
    Yoshizawa, Takashi
    Otaka, Michiro
    Watanabe, Sumio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : S122 - S128
  • [7] Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients
    Corley, Douglas A.
    Kubo, Ai
    Zhao, Wei
    Quesenberry, Charles
    GASTROENTEROLOGY, 2010, 139 (01) : 93 - 101
  • [8] Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists
    Patel, Kajal S.
    Stephany, Brian R.
    Barnes, Julie F.
    Bauer, Seth R.
    Spinner, Michael L.
    PHARMACOTHERAPY, 2017, 37 (12): : 1507 - 1515
  • [9] Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit
    MacLaren, Robert
    Reynolds, Paul M.
    Allen, Richard R.
    JAMA INTERNAL MEDICINE, 2014, 174 (04) : 564 - 574
  • [10] Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients
    Qvigstad, G
    Arnestad, JS
    Brenna, E
    Waldum, HL
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1998, 33 (12) : 1244 - 1248